PROCEPT BioRobotics (NASDAQ:PRCT) Shares Gap Up on Insider Buying Activity

Shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) gapped up before the market opened on Tuesday following insider buying activity. The stock had previously closed at $25.26, but opened at $26.87. PROCEPT BioRobotics shares last traded at $25.46, with a volume of 326,976 shares traded.

Specifically, Director Antal Rohit Desai bought 98,699 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The stock was acquired at an average price of $24.55 per share, for a total transaction of $2,423,060.45. Following the transaction, the director directly owned 426,262 shares of the company’s stock, valued at $10,464,732.10. This represents a 30.13% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Antal Rohit Desai purchased 160,317 shares of the firm’s stock in a transaction that occurred on Friday, March 6th. The stock was purchased at an average price of $23.59 per share, for a total transaction of $3,781,878.03. Following the acquisition, the director owned 327,563 shares of the company’s stock, valued at $7,727,211.17. The trade was a 95.86% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In related news, Director Antal Rohit Desai acquired 167,246 shares of the firm’s stock in a transaction dated Thursday, March 5th. The stock was bought at an average price of $25.58 per share, for a total transaction of $4,278,152.68. Following the acquisition, the director directly owned 167,246 shares of the company’s stock, valued at approximately $4,278,152.68. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on PRCT shares. UBS Group began coverage on PROCEPT BioRobotics in a research report on Friday, December 12th. They set a “buy” rating and a $62.00 price objective on the stock. Oppenheimer reissued a “market perform” rating on shares of PROCEPT BioRobotics in a research report on Thursday, February 26th. Piper Sandler cut their target price on shares of PROCEPT BioRobotics from $50.00 to $28.00 and set an “overweight” rating for the company in a research report on Thursday, February 26th. Wells Fargo & Company lowered their price objective on PROCEPT BioRobotics from $51.00 to $34.00 and set an “overweight” rating on the stock in a research report on Thursday, February 26th. Finally, Wall Street Zen lowered shares of PROCEPT BioRobotics from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Eight analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $40.82.

Key PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Director Antal Rohit Desai executed multiple large open‑market purchases (totaling roughly $10.5M across March 5–9), boosting his stake to ~426k shares — a strong insider signal that management/board sees value at current levels. Read More.
• Positive Sentiment: Robert W. Baird initiated research coverage with a neutral rating and a $30 target; new analyst coverage can improve visibility and trading liquidity even if the note is not a buy call. Read More.
• Neutral Sentiment: Two EVPs (Kevin Waters and Alaleh Nouri) sold small stakes on March 6 (~13.6k shares combined, ~$322k) — likely personal liquidity rather than a signal given the magnitude versus the director’s buys. Read More.
• Negative Sentiment: Multiple law firms (Frank R. Cruz, Levi & Korsinsky, Schall) have opened securities‑fraud investigations related to prior guidance and management statements (citing the Feb. 25 earnings release and prior revenue/handpiece pricing comments). Investigations raise litigation risk, potential disclosures or restatements and create headline risk that can pressure sentiment and multiple. Read More. Read More. Read More.

PROCEPT BioRobotics Trading Up 1.8%

The stock has a market capitalization of $1.45 billion, a PE ratio of -14.92 and a beta of 1.03. The company has a debt-to-equity ratio of 0.14, a quick ratio of 5.77 and a current ratio of 6.85. The stock has a 50-day moving average price of $29.11 and a two-hundred day moving average price of $32.83.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.21). The firm had revenue of $76.38 million for the quarter, compared to analysts’ expectations of $93.70 million. PROCEPT BioRobotics had a negative net margin of 31.02% and a negative return on equity of 25.13%. The business’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.35) EPS. As a group, equities analysts forecast that PROCEPT BioRobotics Corporation will post -1.75 earnings per share for the current year.

Institutional Investors Weigh In On PROCEPT BioRobotics

Large investors have recently bought and sold shares of the company. AQR Capital Management LLC increased its holdings in shares of PROCEPT BioRobotics by 7.3% in the first quarter. AQR Capital Management LLC now owns 18,892 shares of the company’s stock valued at $1,101,000 after purchasing an additional 1,286 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of PROCEPT BioRobotics by 9.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 153,158 shares of the company’s stock valued at $8,923,000 after purchasing an additional 13,767 shares in the last quarter. Intech Investment Management LLC grew its stake in PROCEPT BioRobotics by 54.4% during the 1st quarter. Intech Investment Management LLC now owns 28,389 shares of the company’s stock worth $1,654,000 after purchasing an additional 10,002 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in PROCEPT BioRobotics by 3.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 182,178 shares of the company’s stock worth $10,493,000 after acquiring an additional 5,500 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in shares of PROCEPT BioRobotics by 109.3% during the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 159,874 shares of the company’s stock worth $9,209,000 after acquiring an additional 83,498 shares in the last quarter. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.